{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:04:23Z","timestamp":1793736263501,"version":"4.6.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Gleason grading system is the cornerstone of risk stratification and clinical decision-making in prostate cancer patients. In the last decade, new insights on quantitative grading and the importance of particular growth patterns have further optimized pathological tumor grading. This review provides an update on the latest grading recommendations and discusses contemporary research directions.<\/jats:p>","DOI":"10.1007\/s00292-025-01450-w","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:06:14Z","timestamp":1753869974000},"page":"10-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current grading of prostate cancer","Aktuelle Graduierung des Prostatakarzinoms. Englische Version"],"prefix":"10.1007","volume":"46","author":[{"given":"Yosamin Gonzalez","family":"Belisario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert J. L. H.","family":"van Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"3","key":"1450_CR1","first-page":"125","volume":"50","author":"DF Gleason","year":"1966","unstructured":"Gleason DF (1966) CLassification of prostatic carcinomas. Cancer Chemother Rep 50(3):125\u2013128","journal-title":"Cancer Chemother Rep"},{"issue":"9","key":"1450_CR2","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","volume":"29","author":"J Epstein","year":"2005","unstructured":"Epstein J et al (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29(9):1228\u20131242","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"1450_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"J Epstein","year":"2016","unstructured":"Epstein J et al (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 40(2):244\u2013252","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"1450_CR4","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1464-410X.2012.11611.x","volume":"111","author":"PM Pierorazio","year":"2013","unstructured":"Pierorazio PM et al (2013) Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111(5):753\u2013760","journal-title":"BJU Int"},{"key":"1450_CR5","volume-title":"WHO classification of Tumors","author":"GJ Netto","year":"2022","unstructured":"Netto GJ, Armin MB, Kench JG et al (2022) Chapter 4: Tumours of the prostate. In: Srigley JR, Amin MB, Rubin MA, Tsuzuki T (Hrsg) WHO classification of Tumors, 5.\u00a0Aufl. Bd. 8","edition":"5"},{"issue":"8","key":"1450_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"GJLH van Leenders","year":"2020","unstructured":"van Leenders GJLH et al (2020) The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 44(8):87\u201399","journal-title":"Am J Surg Pathol"},{"key":"1450_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.eururo.2024.02.017","volume":"86","author":"A Cimadamore","year":"2024","unstructured":"Cimadamore A et al (2024) How To Report the Minor Component of a\u00a0High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the \u201cTertiary\u201d Terminology? Eur Urol 86:291\u2013294","journal-title":"Eur Urol"},{"issue":"4","key":"1450_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.eururo.2015.10.029","volume":"69","author":"G Sauter","year":"2016","unstructured":"Sauter G et al (2016) Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. Eur Urol 69(4):592\u2013598","journal-title":"Eur Urol"},{"issue":"1","key":"1450_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pathol.2018.10.003","volume":"51","author":"L Egevad","year":"2019","unstructured":"Egevad L et al (2019) Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Pathology 51(1):11\u201320","journal-title":"Pathology"},{"issue":"3","key":"1450_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00428-019-02574-0","volume":"475","author":"JG Kench","year":"2019","unstructured":"Kench JG et al (2019) Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. Virchows Arch 475(3):263\u2013277","journal-title":"Virchows Arch"},{"issue":"1","key":"1450_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ajcp\/aqad005","volume":"160","author":"J Ordner","year":"2023","unstructured":"Ordner J et al (2023) Significance of the Percentage of Gleason Pattern 4 at Prostate Biopsy in Predicting Adverse Pathology on Radical Prostatectomy: Application in Active Surveillance. Am J Clin Pathol 160(1):35\u201340","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"1450_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.eururo.2017.01.015","volume":"73","author":"G Sauter","year":"2018","unstructured":"Sauter G et al (2018) Integrating Tertiary Gleason\u00a05 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. Eur Urol 73(5):674\u2013683","journal-title":"Eur Urol"},{"issue":"6","key":"1450_CR13","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00428-022-03301-y","volume":"480","author":"N Seyrek","year":"2022","unstructured":"Seyrek N et al (2022) Alternative prostate cancer grading systems incorporating percent pattern 4\/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy. Virchows Arch 480(6):1149\u20131157","journal-title":"Virchows Arch"},{"issue":"1","key":"1450_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.juro.2018.07.062","volume":"201","author":"LW Dean","year":"2019","unstructured":"Dean LW et al (2019) Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group\u00a02 Prostate Cancer. J\u00a0Urol 201(1):77\u201382","journal-title":"J Urol"},{"issue":"1","key":"1450_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eururo.2024.01.005","volume":"86","author":"AJ Vickers","year":"2024","unstructured":"Vickers AJ et al (2024) Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group\u00a02\u20134 Prostate Cancer. Eur Urol 86(1):1\u20133","journal-title":"Eur Urol"},{"issue":"6","key":"1450_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/modpathol.2016.49","volume":"29","author":"C Kweldam","year":"2016","unstructured":"Kweldam C et al (2016) Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod Pathol 29(6):630\u2013636","journal-title":"Mod Pathol"},{"key":"1450_CR17","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.ejca.2014.03.009","volume":"50","author":"D Trudel","year":"2014","unstructured":"Trudel D et al (2014) Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a\u00a0contemporary cohort. Eur J Cancer 50:1610\u20131616","journal-title":"Eur J Cancer"},{"issue":"8","key":"1450_CR18","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1097\/PAS.0000000000001728","volume":"45","author":"T van der Kwast","year":"2021","unstructured":"van der Kwast T et al (2021) ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. Am J Surg Pathol 45(8):1118\u20131126","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"1450_CR19","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41379-022-01009-7","volume":"35","author":"E Chan","year":"2022","unstructured":"Chan E et al (2022) Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25\u202fmm diameter as an optimal definition for \u201clarge\u201d cribriform prostatic adenocarcinoma. Mod Pathol 35(8):1092\u20131100","journal-title":"Mod Pathol"},{"issue":"1","key":"1450_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41379-018-0157-9","volume":"32","author":"E Hollemans","year":"2018","unstructured":"Hollemans E et al (2018) Large cribriform growth pattern identifies ISUP grade\u00a02 prostate cancer at high risk for recurrence and metastasis. Mod Pathol 32(1):139\u2013146","journal-title":"Mod Pathol"},{"issue":"1","key":"1450_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1309\/AJCPZ7WBU9YXSJPE","volume":"136","author":"K Iczkowski","year":"2011","unstructured":"Iczkowski K et al (2011) Digital Quantification of Five High-Grade Prostate Cancer Patterns, Including the Cribriform Pattern, and Their Association With Adverse Outcome. Am J Clin Pathol 136(1):98\u2013107","journal-title":"Am J Clin Pathol"},{"key":"1450_CR22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/his.15102","volume":"84","author":"N Greenland","year":"2024","unstructured":"Greenland N et al (2024) Large cribriform glands (\u3009\u202f0.25\u202fmm diameter) as a\u00a0predictor of adverse pathology in men with Grade Group\u00a02 prostate cancer. Histopathology 84:614\u2013623","journal-title":"Histopathology"},{"issue":"7","key":"1450_CR23","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/his.14658","volume":"80","author":"L Rijstenberg","year":"2022","unstructured":"Rijstenberg L et al (2022) Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies. Histopathology 80(7):1041\u20131049","journal-title":"Histopathology"},{"key":"1450_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2019.07.051","volume":"77","author":"GJLH van Leenders","year":"2020","unstructured":"van Leenders GJLH et al (2020) Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. Eur Urol 77:191\u2013198","journal-title":"Eur Urol"},{"issue":"1","key":"1450_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.clgc.2023.07.013","volume":"22","author":"MR Downes","year":"2023","unstructured":"Downes MR et al (2023) Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools. Clin Genitourin Cancer 22(1):47\u201355","journal-title":"Clin Genitourin Cancer"},{"key":"1450_CR26","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1002\/1097-0142(19861015)58:8<1714::AID-CNCR2820580823>3.0.CO;2-M","volume":"58","author":"JE McNeal","year":"1986","unstructured":"McNeal JE et al (1986) Cribriform Adenocarcinoma of the Prostate. Cancer 58:1714\u20131719","journal-title":"Cancer"},{"key":"1450_CR27","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/modpathol.3800702","volume":"19","author":"C Guo","year":"2006","unstructured":"Guo C et al (2006) Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol 19:1528\u20131535","journal-title":"Mod Pathol"},{"key":"1450_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/his.13273","volume":"71","author":"R Shah","year":"2017","unstructured":"Shah R et al (2017) Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a\u00a0comparative clinicopathological and molecular study with a\u00a0proposal to expand the morphological spectrum of intraductal carcinoma. Histopathology 71:693\u2013702","journal-title":"Histopathology"},{"issue":"4","key":"1450_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/PAS.0000000000000794","volume":"41","author":"R Hickman","year":"2017","unstructured":"Hickman R et al (2017) Atypical intraductal cribriform proliferations of the prostate exhibit similar molecular and clinicopathologic characteristics as intraductal carcinoma of the prostate. Am J Surg Pathol 41(4):550\u2013556","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"1450_CR30","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1097\/PAS.0000000000000736","volume":"40","author":"J McKenney","year":"2016","unstructured":"McKenney J et al (2016) Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. Am J Surg Pathol 40(11):1439\u20131456","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"1450_CR31","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/his.15231","volume":"85","author":"J Nguyen","year":"2024","unstructured":"Nguyen J et al (2024) Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage. Histopathology 85(4):598\u2013613","journal-title":"Histopathology"},{"issue":"11","key":"1450_CR32","doi-asserted-by":"publisher","first-page":"100563","DOI":"10.1016\/j.modpat.2024.100563","volume":"37","author":"K Faryna","year":"2024","unstructured":"Faryna K (2024) e.a, Evaluation of Artificial Intelligence-Based Gleason Grading Algorithms \u201cin the Wild\u201d. Mod Pathol 37(11):100563","journal-title":"Mod Pathol"},{"issue":"3","key":"1450_CR33","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41379-020-0640-y","volume":"34","author":"W Bulten","year":"2021","unstructured":"Bulten W et al (2021) Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. Mod Pathol 34(3):660\u2013671","journal-title":"Mod Pathol"},{"issue":"1","key":"1450_CR34","doi-asserted-by":"publisher","first-page":"14904","DOI":"10.1038\/s41598-020-71942-7","volume":"10","author":"P Ambrosini","year":"2020","unstructured":"Ambrosini P et al (2020) Automated detection of cribriform growth patterns in prostate histology images. Sci Rep 10(1):14904","journal-title":"Sci Rep"}],"container-title":["Die Pathologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01450-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-025-01450-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01450-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:27:41Z","timestamp":1765373261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-025-01450-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":34,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1450"],"URL":"https:\/\/doi.org\/10.1007\/s00292-025-01450-w","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"12 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.G.\u00a0Belisario and G.J.L.H.\u00a0van Leenders declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}